Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Polycystic Ovarian Syndrome-Pipeline Review, H2 2016

Polycystic Ovarian Syndrome-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Polycystic Ovarian Syndrome-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Polycystic Ovarian Syndrome-Pipeline Review, H2 2016', provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome

The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects

The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Polycystic Ovarian Syndrome Overview 7

Therapeutics Development 8

Pipeline Products for Polycystic Ovarian Syndrome-Overview 8

Pipeline Products for Polycystic Ovarian Syndrome-Comparative Analysis 9

Polycystic Ovarian Syndrome-Therapeutics under Development by Companies 10

Polycystic Ovarian Syndrome-Therapeutics under Investigation by Universities/Institutes 11

Polycystic Ovarian Syndrome-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Polycystic Ovarian Syndrome-Products under Development by Companies 16

Polycystic Ovarian Syndrome-Products under Investigation by Universities/Institutes 17

Polycystic Ovarian Syndrome-Companies Involved in Therapeutics Development 18

Addex Therapeutics Ltd 18

Crinetics Pharmaceuticals, Inc. 19

EffRx Pharmaceuticals S.A. 20

Euroscreen S.A. 21

Merck KGaA 22

Millendo Therapeutics, Inc. 23

Vicore Pharma AB 24

Polycystic Ovarian Syndrome-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

C-21-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

choriogonadotropin alfa-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ESN-364-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

JDSCR-004-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

KDT-501-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

metformin hydrochloride-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MLE-4901-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule to Antagonize FSH Receptor for Women's Health-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Polycystic Ovarian Syndrome-Dormant Projects 47

Polycystic Ovarian Syndrome-Discontinued Products 48

Polycystic Ovarian Syndrome-Product Development Milestones 49

Featured News & Press Releases 49

Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome 49

Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome 49

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 50

Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 50

Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 51

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 51

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 51

Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 52

Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 52

Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8

Number of Products under Development for Polycystic Ovarian Syndrome-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8

Number of Products under Development for Polycystic Ovarian Syndrome-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Comparative Analysis by Unknown Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Polycystic Ovarian Syndrome-Pipeline by Addex Therapeutics Ltd, H2 2016 18

Polycystic Ovarian Syndrome-Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 19

Polycystic Ovarian Syndrome-Pipeline by EffRx Pharmaceuticals S.A., H2 2016 20

Polycystic Ovarian Syndrome-Pipeline by Euroscreen S.A., H2 2016 21

Polycystic Ovarian Syndrome-Pipeline by Merck KGaA, H2 2016 22

Polycystic Ovarian Syndrome-Pipeline by Millendo Therapeutics, Inc., H2 2016 23

Polycystic Ovarian Syndrome-Pipeline by Vicore Pharma AB, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Polycystic Ovarian Syndrome-Dormant Projects, H2 2016 47

Polycystic Ovarian Syndrome-Discontinued Products, H2 2016 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Crinetics Pharmaceuticals, Inc.

EffRx Pharmaceuticals S.A.

Euroscreen S.A.

Merck KGaA

Millendo Therapeutics, Inc.

Vicore Pharma AB

Polycystic Ovarian Syndrome Therapeutic Products under Development, Key Players in Polycystic Ovarian Syndrome Therapeutics, Polycystic Ovarian Syndrome Pipeline Overview, Polycystic Ovarian Syndrome Pipeline, Polycystic Ovarian Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com